MedBulletinsAura Celeste
GI

What's next in gastroenterology — November 17, 2026

🎧 Listen to this issueAudio newscast · 4:03 min

This edition gathers four milestones with verifiable dates between late November 2026 and March 2027: topline results from a phase 3 MASH trial, two FDA decisions (gastrointestinal stromal tumor and pediatric vedolizumab), and the ECCO 2027 congress. Each item lists its official source and how certain the date is.

1. Lanifibranor in MASH with F2–F3 fibrosis: NATiV3 results

[Ongoing trial] [International] [Estimated date: fourth quarter of 2026, per Inventiva]
What it is: randomized, double-blind, placebo-controlled phase 3 trial of 1,009 adults with biopsy-proven non-cirrhotic MASH and F2–F3 fibrosis, comparing oral lanifibranor (a pan-PPAR agonist) 800 mg and 1,200 mg daily with placebo over 72 weeks. The primary endpoint is a composite of MASH resolution together with at least one-stage fibrosis improvement at week 72. If the results are favorable, the company anticipates a regulatory submission in the first half of 2027.
What problem it solves: MASH with advanced fibrosis progresses to cirrhosis; resmetirom and semaglutide already have FDA accelerated approval for noncirrhotic MASH with moderate to advanced (F2–F3) fibrosis, and further treatment options are needed.
Critical take: manufacturer-funded trial with a surrogate histological endpoint; the result may be negative and, even if positive, a regulatory submission would not come before 2027.

Sources

2. Bezuclastinib + sunitinib in GIST after imatinib

[Pending regulatory decision] [United States] [Confirmed date: November 30, 2026 (PDUFA target action date, per Cogent Biosciences)]
What it is: the FDA is reviewing, under priority review, bezuclastinib (a KIT inhibitor) plus sunitinib for GIST previously treated with imatinib. In the randomized, open-label phase 3 PEAK trial versus sunitinib alone in imatinib-resistant or -intolerant patients, progression-free survival (blinded independent central review) had an HR of 0.50 (95% CI 0.39–0.65; p < 0.0001), with medians of 16.5 versus 9.2 months.
What problem it solves: second-line therapy after imatinib failure or intolerance is currently sunitinib monotherapy, with limited disease control.
Critical take: open-label, sponsor-run trial (with blinded central assessment of progression) and still-immature overall survival; the added toxicity of two tyrosine kinase inhibitors and access outside the U.S. need weighing.

Sources

3. Intravenous vedolizumab in pediatric ulcerative colitis and Crohn's disease

[Pending regulatory decision] [United States and European Union] [Estimated date: first quarter of 2027, per Takeda]
What it is: the FDA accepted the sBLA for IV vedolizumab in moderately to severely active ulcerative colitis and Crohn's disease in children aged 2 years and older (PDUFA date in the first quarter of 2027); Takeda has also submitted a marketing authorization application to the EMA. It is supported by the randomized, double-blind phase 3 KEPLER (UC) and WEBB (Crohn's) trials in patients aged 2 to 17, with clinical remission at week 54 as the primary endpoint (plus endoscopic response in WEBB).
What problem it solves: vedolizumab is approved only in adults, and approved treatment options for children with IBD are limited (mainly anti-TNF agents).
Critical take: manufacturer-run studies; WEBB was listed as ongoing when the filing was announced, and FDA approval does not automatically translate into coverage in our setting.

Sources

4. ECCO 2027 Congress in Copenhagen

[Congress] [Europe] [Confirmed date: March 3–6, 2027]
What it is: the 22nd Congress of the European Crohn's and Colitis Organisation at the Bella Center, Copenhagen; scientific program March 4–6 and educational program March 3–5. The program announces summary presentations of new ECCO guidelines.
What problem it solves: it is one of the main venues for phase 3 IBD data and European guidelines that later shape practice and formularies.
Critical take: the official website itself shows a different date in one banner (March 1–4), although the detailed program states March 3–6, so confirm before planning; the announced guidelines have no published titles yet.

Sources

Get every issue by email

Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.